SCHEMBL19747594

SCHEMBL19747594

COc1ccc(CNc2nc(C(F)(F)F)cn3c(Br)cnc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
TP53 P04637 3/20 0.47
FABP4 P15090 1/20 0.45
CCNE2 O96020 2/20 0.44
CCNE1 P24864 2/20 0.44
CDK2 P24941 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
THRB P10828 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
USP1 O94782 1/20 0.41
WDR48 Q8TAF3 1/20 0.41
PTGS2 P35354 1/20 0.41
PTK2 Q05397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20934814 0.76 CCNE2 (0.47) MAPTTP53CCNE2CCNE1CDK2
SCHEMBL1674072 0.76 ZAP70 (0.46) MAPTTP53CCNE2CCNE1CDK2
SCHEMBL20919599 0.76 CDK1 (0.47) MAPTTP53CCNE2CCNE1CDK2
SCHEMBL19747188 0.74 CCNE2 (0.47) MAPTCCNE2CCNE1CDK2KDM4E
SCHEMBL14450054 0.72 KDM4E (0.45) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL8241011 0.72 BCDIN3D (0.43) MAPTTP53CDK2SMN1; SMN2KDM4E
SCHEMBL19747921 0.71 MAPK8 (0.44) TP53FABP4SMN1; SMN2KDM4EALDH1A1
SCHEMBL12493485 0.71 KDM4E (0.37) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5550039 0.70 GSK3A (0.46) MAPTTP53FABP4CCNE2CCNE1
SCHEMBL2177269 0.70 STK17B (0.47) MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516065-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2026-01-06 US disclosed
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2024-07-11 US disclosed
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors INCYTE CORPORATION (US) 2024-07-09 US disclosed
CN-118063470-A Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-05-24 CN disclosed
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2024-03-12 US disclosed
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-08-11 US disclosed
US-20220213107-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-07-07 US disclosed
US-20220213107-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-07-07 US disclosed
EP-4006034-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2022-06-01 EP disclosed
EP-4006034-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2022-06-01 EP disclosed
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-05-23 US disclosed
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-05-23 US disclosed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 WO disclosed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 WO disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 US disclosed
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-04-25 US disclosed
US-10138248-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors INCYTE CORPORATION (US) 2018-11-27 US disclosed
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2018-01-11 US disclosed
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2018-01-11 US disclosed
WO-2017223414-A1 HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS INCYTE CORPORATION (US) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030885-B2 Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors PIK3CG, PIK3CD, PIK3R5 MAPT 3384/4885TP53 919/4885FABP4 4758/4885
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD MAPT 1854/4885TP53 1153/4885FABP4 3151/4885
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD MAPT 1854/4885TP53 1153/4885FABP4 3151/4885
US-10138248-B2 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors PIK3CA, PIK3CG, PIK3CD MAPT 3278/4885TP53 747/4885FABP4 4786/4885
US-20190119287-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD MAPT 3639/4885TP53 982/4885FABP4 4841/4885
US-20220213107-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD MAPT 1854/4885TP53 1153/4885FABP4 3151/4885
US-20180009816-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD MAPT 3639/4885TP53 982/4885FABP4 4841/4885
US-20220251087-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD MAPT 3639/4885TP53 982/4885FABP4 4841/4885
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors PIK3R5, PIK3CG, PIK3CD MAPT 1679/4885TP53 1101/4885FABP4 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.